ArticleFrontiers in oncology2025
Cutaneous adverse events associated with the efficacy and benefit of immune checkpoint inhibitors: a systematic review and meta-analysis.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Cutaneous immune-related adverse events (cirAEs) are associated with improved survival in tumor patients undergoing immune checkpoint inhibitors (ICIs) therapy, while inconsistent evidence has been reported across tumor subtypes. This study aimed to evaluate the association of cirAEs and their subtypes with cancer prognosis. Design: Systematic review and meta-analysis. Methods: Four databases including Cochrane Library, Embase, PubMed and Web of Science were searched for original publications from inception to April 30, 2024. A meta-analysis was carried out for overall survival (OS) and progression-free survival (PFS) of patients, and pooled hazard ratios (HRs) with 95% confidential intervals (CIs) were calculated. Subgroup analyses involving cirAEs subtype, cancer type, ICIs type, geographic region of patients, and study quality were performed. Results: Forty-five studies comprising a total of 26817 patients with ICIs treatment were included in the study. The occurrence of cirAEs was associated with prolonged OS (HR, 0.54 [95%CI, 0.46-0.63]; Conclusions: The occurrence of cirAEs, especially in vitiligo and rash, predicted a significant survival benefits among tumor patients receiving ICIs therapy, especially in MM, RCC and NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.